Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Walgreens

DEERFIELD, Ill. & BURLINGTON, N.C.--(BUSINESS WIRE)--As part of Walgreens ongoing efforts to increase access to COVID-19 testing in communities across the U.S., the company announced today it has entered into an agreement with Labcorp™ to sell Pixel by Labcorp COVID-19 PCR Test Home Collection Kits over-the-counter in up to 6,000 Walgreens stores nationwide beginning in spring of this year. Walgreens is making significant strides to increase on-site testing capacity at more than 5,000 Walgreens

Walgreens to Make Pixel by Labcorp™ COVID-19 PCR Test Home Collection Kit Available Over-The-Counter at Stores Nationwide

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Thursday, Feb. 25 at 1:30 p.m. ET. A live webcast of the presentation will be available via the company website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global life sciences c

Labcorp is Scheduled to Speak at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference

LabCorp's (LH) new antigen test is the newest development to detect COVID-19 infection at every single stage, from diagnostic testing to vaccination trails.

LabCorp's (LH) New Antigen Test to Spot Active COVID-19 Virus

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the availability of a new laboratory-based antigen test that will help doctors determine if an individual is actively infected with COVID-19. Developed by DiaSorin, the antigen test is available to patients through a doctor's order and allows for testing to determine if individuals are still infected with and could spread COVID-19. The test is performed by a doctor or other healthcare

Labcorp Adds High Sensitivity Antigen Test to Screen for Active COVID-19 Infection

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Amy Summy, executive vice president and chief marketing officer, was recognized on the 2021 Forbes CMO Next list for her leadership during the COVID-19 crisis, while also spearheading the rebranding strategy that highlighted the power of Labcorp's combined diagnostic and drug development businesses. Forbes also recognized Amy's work in launching several products, including the com

Amy Summy, Chief Marketing Officer of Labcorp, Named to Forbes' CMO Next

Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q4 2020 Results - Earnings Call Transcript

The laboratory services giant continued to profit mightily from its COVID-19 testing business.

Here's How Labcorp Trounced Wall Street Estimates in Q4

LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.

LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading life sciences company, today announced results for the fourth quarter and year ended December 31, 2020, and full year 2021 guidance. “Labcorp's science and innovation throughout the pandemic led to strong performance in the quarter and for the full year. In addition to our leadership in testing, our capabilities are being leveraged to identify variants to the virus through genetic sequencing and to support biotechnology and pharma

Labcorp Announces 2020 Fourth Quarter and Full Year Results and Provides 2021 Guidance

LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why LabCorp (LH) Might Surprise This Earnings Season

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointments of Prasanth Reddy, MD, MPH, and Robert Phillips, PhD, to its oncology team, advancing Labcorp's leadership position and capabilities in cancer diagnosis, treatment, and drug development. Dr. Reddy will serve as senior vice president and enterprise oncology head of the company's enterprise oncology unit, and Dr. Phillips will be vice president and head of enterprise onc

Labcorp Announces Key Appointments to Oncology Leadership Team

LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.

Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings

LabCorp is benefitting from the recent surge in COVID infections, and the new COVID variants should keep up demand for its services. It continues to build its healthcare footprint and expand its moat.

Why LabCorp Is Set For Long-Term Success

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE® magazine's 2021 List of World's Most Admired Companies, making the annual list for the third time. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is given to top executives, directors, and financial analysts to identify the companies that enjoy the strongest reputations within their industries and acro

Labcorp Named to FORTUNE® Magazine's 2021 ‘World's Most Admired Companies,' Making the Annual List for the Third Time

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp, (NYSE: LH), a leading global life sciences company, announced today that Dr. Deborah Ann Sesok-Pizzini has been appointed Chief Medical Officer of Labcorp Diagnostics, following the retirement of Dr. Dot Adcock in April 2021. Dr. Sesok-Pizzini assumed the role starting on January 11, 2021. Dr. Sesok-Pizzini joins Labcorp with over two decades of experience in healthcare. Prior to joining Labcorp, she held multiple appointments with The Children's Hosp

Labcorp Appoints Dr. Deborah Ann Sesok-Pizzini as Chief Medical Officer, Labcorp Diagnostics

Abbott Labs

Becton, Dickinson and Co.

Quest Diagnostics

Hologic

QuidelOrtho Corp

QIAGEN

The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.

Testing Space in Focus Again Thanks to New Wave of Coronavirus

"We still have to understand a lot more about the vaccines, know what to measure, how to measure," LabCorp CEO Adam Schechter told CNBC.

LabCorp CEO says Covid vaccine recipients don't need to be tested for antibodies afterward

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its fourth quarter and full year 2020 financial results before the market opens on Thursday, Feb. 11, 2021, and then will host a conference call and webcast beginning at 9:00 a.m. ET to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing 1-877

Labcorp to Announce Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been awarded a contract from the Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of samples of SARS-CoV-2, the virus that causes COVID-19. This sequencing will aid the CDC in its goal of conducting a large-scale longitudinal genomic survey of the virus using a random set of samples collected from across the United States. The survey aims to pr

Labcorp Awarded CDC Contract to Study Variants of COVID-19 Virus and Improve Public Health Response

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Dr. Brian Caveney, chief medical officer and president of Labcorp Diagnostics, was recognized by Modern Healthcare as one of the 100 most influential people in healthcare in 2020. According to Modern Healthcare, editors of the publication and its readers selected the most innovative and resilient candidates who influenced the course that healthcare took during a global crisis and

Brian Caveney, Chief Medical Officer and President of Labcorp Diagnostics, Named to Modern Healthcare's 100 Most Influential People in Healthcare

Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.

LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12 at 8:20 a.m. (EST). A live webcast of the fireside chat will be available via the Company website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global life sciences company that provides vital

Labcorp Is Scheduled to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference

Asbury Automotive Group

Knight-Swift Transportation Holdings

Office Depot

Top Ranked Growth Stocks to Buy for January 4th

Hibbett Sports

Owens & Minor

Top Ranked Growth Stocks to Buy for December 30th

Boise Cascade

General Motors

Honda

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.

News for Labcorp Holdings Inc Stock (LH)